MannKind Corp. (MNKD)

[COO2002COO]

Shantha Biotechnics, a Sanofi company, will set up a `460-crore manufacturing facility

SHANTHA TO SET UP `460-CR FACILITY

METRO NEWS / HYDERABAD : Shantha Biotechnics, a Sanofi company, will set up a `460-crore manufacturing facility where Insuman, a human insulin product from Sanofi's range of diabetes treatment will be manufactured. Sanofi will make an investment of `460 crore in the facility. This will be Sanofi's second plant apart from its existing Insuman manufacturing plant in Frankfurt. The construction of the 13,400 square-metre building will begin immediately, with the site fully operational by 2019.

Harish Iyer, CEO, Shantha Biotechnics said, “For the first time, we will be able to manufacture insulin – in cartridges here. The new high technology facility will benefit from our existing biotechnology production expertise. This state-of-the-art facility will have the capability to ramp up manufacturing volumes to 60 million Insuman cartridges per year, within two to three years of commercial manufacturing.”

Shailesh Ayyangar, managing director - India and vice president - South Asia, Sanofi said, “The technology transfer and a successful collaborative effort within the Sanofi Group, underline our commitment to investing and ‘making in India’. Many more diabetic patients in India can have easier access to better disease management and quality of life post completion of the facility.” Type 2 Diabetes is a prominent Non Communicable Disease. Globally, diabetes afflicts close to 382 million people with India alone accounting for over 65 million cases.

The number of people with diabetes in India is expected to rise to 109 million by 2035. Out of the estimated 42 million patients on insulin in India, 3.3 million patients are prescribed Regular Human Insulin for diabetes management and control. The production of Insuman in this facility is expected to meet local and international demand.

http://metroindia.com/Details.aspx?id=60537



Hyderabad-based Shantha Biotechnics, a subsidiary of French pharmaceutical company Sanofi, is setting up an insulin manufacturing plant at an investment of Rs 460 crore near here. The plant is expected to be operational by 2019.

The facility will manufacture Insuman, a human insulin product from the portfolio of Sanofi’s diabetes treatments. This will be the French global pharma major’s second Insuman manufacturing plant in the world. Chief minister K Chandrasekhar Rao today laid the foundation stone for the plant. The project is coming up in his home constituency of Gajwel in the neighbouring Medak district.

KI Varaprasada Reddy, founder and chairman of Shantha, said this would be a new technology facility where insulin would be manufactured in cartridges. According to him, it has a capacity to ramp up manufacturing volumes to 60 million cartridges a year in 2-3 years of commercial manufacturing. The cartridges manufactured in this plant will be priced at Rs 11 per day. Sanofi India launched Insuman cartridges in 2011.

Sanofi Pasteur Holding acquired Shantha in 2009 as the homegrown vaccine maker’s products complement the former’s portfolio. Four of Shantha’s licensed vaccines, including pentavalent vaccine (Shan5), are WHO-qualified. Further, Sanofi Pasteur and Shantha are also developing a new paediatric combination vaccine based on Shan5 paediatric vaccine incorporating Sanofi Pasteur’s inactivated polio vaccine in order to secure polio eradication, according to the company.

http://www.business-standard.com/article/companies/sanofi-subsidiary-to-set-up-rs-460-cr-insulin-manufacturin-facility-in-telangana-115012901055_1.html